Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
about
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imagingCurrent and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy.Impact of the arterial input function on microvascularization parameter measurements using dynamic contrast-enhanced ultrasonographyEstimation of intra-operator variability in perfusion parameter measurements using DCE-US.Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling.The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic ratsTemporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancerDynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and ExamplesNon-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts.Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.Review of treatment assessment using DCE-MRI in breast cancer radiation therapy.Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancerVascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in miceRat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.Dependence of DCE-MRI biomarker values on analysis algorithm.Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?Detecting microvascular changes in the mouse spleen using optical computed tomography.Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study.Value of Dynamic Contrast-Enhanced MRI to Detect Local Tumor Recurrence in Primary Head and Neck Cancer Patients.Intravoxel Incoherent Motion MR Imaging in the Head and Neck: Correlation with Dynamic Contrast-Enhanced MR Imaging and Diffusion-Weighted Imaging.Tumour vascular disrupting agents: combating treatment resistance.Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.Imaging tumour physiology and vasculature to predict and assess response to heat.An update on the clinical development of drugs to disable tumor vasculature.Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.Imaging analysis of the in vivo bioreactor: a preliminary study.Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
P2860
Q27346895-D2C6A418-6E4E-4E51-A4C0-D7D7CF5BB5B2Q30460977-F25D664D-3FA0-416A-9E6B-F45EC0733A48Q30464680-74974E53-C59A-40DE-93F3-B05C6D52C8A2Q30475764-72E812DA-E532-4096-8D35-4A660DE51F62Q30810422-07F8AB92-A287-44B0-A24F-B07B52B87092Q31049713-AE39C72D-4BBA-448D-8CDC-8BC3333F6019Q33217481-D81C85AA-8DDD-418C-98A0-ACD6235A48C0Q33286035-3E9449F5-268C-4F6B-B987-89FFDC66E6D4Q33474971-A9E75BE0-E781-4156-B9D7-C621FD34F774Q33510695-338E11E9-8F7E-474A-90A0-478BC848E62BQ33863907-795DB14B-035B-401E-8E07-19C72DA33DD7Q34145257-6C415CC1-7D01-4826-AD3C-B375E09B391FQ34367593-0C83DBEA-C2C8-48FB-8FD9-977AE58A75D8Q34538659-D7745BBE-E3DB-4BD8-B378-B1612AEF5CFAQ34633674-228AAA51-4941-4475-A1F5-3B3B1FA070BDQ35052189-41077450-F688-466A-8870-8CB4AEEB8E90Q35170356-319ECA17-5932-4B74-AC38-D6DCA5C86CBBQ35711964-91516CC4-D66E-4512-BA8E-F2432682496BQ35879814-91179FE8-5750-453C-B55A-0414CF2A6D66Q35974239-F5258036-69D9-4354-A1C0-8B245B1CAB94Q36611627-453B5A03-C82A-41A3-8E04-3CF15593B68EQ36613314-47A2A02E-D165-4809-AB64-E43F463387A1Q36614213-87C0C3FC-7CC9-4B92-B68D-3F10B17C9957Q36615531-6F4A2E62-5D5A-4442-B9FB-B82AC4B5F0B2Q36702766-100241F6-2616-4D3E-8BB4-651B3EB54E25Q36785948-063D4685-E8B4-4DF2-84D6-9914752C5D19Q36993641-79197561-AA52-4284-AB33-2FF332F50EFCQ37223087-B27E4003-5ADD-4D06-AE4D-79C513646FDAQ37280244-79EF9A2E-D00B-4134-BDF7-BCC74510D519Q37316228-55D54074-ED03-4049-81AE-CF354AB167C4Q37344824-4E8E93D0-2DFF-45EB-8F7D-99498D6DDE6BQ37418739-1D454727-5E6C-40E0-B6E1-F5368DDBFABEQ37592390-7D4DA49B-5DEC-4098-9655-0D8CA275949DQ37730090-DC64F8FC-7459-4B36-BAAC-91B849F95112Q38088732-B0895898-EA3C-4F28-B751-E9F620F5ABAEQ38168371-023809A8-C4CB-482C-AA70-865A12AA000EQ39657204-DC26A3F3-DF7F-4AE7-B922-74B7AEBF7F08Q40087261-762C8B4F-DC1E-4052-89F8-97D9E28D9642Q41552582-143B40C6-9B49-4CE0-9A36-7895FBB1EE9FQ42497254-667D7A53-A5FA-43A8-AD74-1AA13BE4B507
P2860
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Magnetic resonance imaging mea ...... scular-targeting agent ZD6126.
@en
type
label
Magnetic resonance imaging mea ...... scular-targeting agent ZD6126.
@en
prefLabel
Magnetic resonance imaging mea ...... scular-targeting agent ZD6126.
@en
P2093
P1476
Magnetic resonance imaging mea ...... scular-targeting agent ZD6126.
@en
P2093
Anderson J Ryan
Andrew Stone
Catherine Wheeler
David C Blakey
Jeffrey L Evelhoch
Joanna Leadbetter
John C Waterton
Lisa Polin
Patricia M LoRusso
Peter Langmuir
P304
P356
10.1158/1078-0432.CCR-03-0417
P407
P577
2004-06-01T00:00:00Z